AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← KRAS / RAS targeting: from platform to Phase 3

elisrasib

Clinical trial

11 people · 11 posts · 1 abstract

Records

Drug / trial	Readout	Setting
elisrasibelisrasib	G12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%	D3S-001 · floor disclosure

Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).

Other cases in this chapter

daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
RM-055Active in daraxonrasib-resistant and RAS-amplification models

Evidence

CT303NCT05410145

Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study

Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque

Read the abstract →

Floor

Apr 22Wed

Wednesday · 2 items

08:43
x.com@Score6060
Byoung Chul Cho shared updated phase I/II clinical trial results evaluating elisrasib in patients with locally advanced or metastatic NSC...
Same topic elisrasib · 11 peopleHeat 40 likes1 reply3 reposts
05:15
x.com@Score6060
🆕 Next-gen KRAS G12C inhibitor elisrasib induced:
Same topic elisrasib · 11 people KRASHeat 30 likes1 reply2 reposts

Apr 21Tue

Tuesday · 2 items

20:55
Lung Cancers Today@Lung_CancersScore6060
Elisrasib showed “robust and durable efficacy” in patients with previously treated locally advanced or metastatic KRAS G12C NSCLC, accord...
Same topic elisrasib · 11 people KRAS #LCSM #NSCLCHeat 31 like0 replies2 reposts
00:25
cancer_navi@cancer_naviScore6060
Breaking news from AACR: Single-agent administration of the KRAS G12C inhibitor elisrasib demonstrated tolerability and promising antitum...
Same topic elisrasib · 11 people KRAS #LUNGHeat 1211 likes0 replies1 repost

Apr 20Mon

Monday · 6 items

22:25
Stephen V Liu, MD@StephenVLiuScore6060
Dr. Byoung Chul Cho presented elisrasib (D3S-001), next gen KRAS G12C inhibitor in NSCLC at #AACR26. Images not posted by request. In 84 ...
Same topic elisrasib · 11 people KRASHeat 00 likes0 replies0 reposts
14:59
Erik J.@PrblmXpertScore6060
This 3+ year durability data marks a paradigm shift for advanced NSCLC. I consider Elisrasib's efficacy clear proof that sustained precis...
Same topic elisrasib · 11 peopleHeat 00 likes0 replies0 reposts
13:51
Young Kwang Chae, MD, MPH, MBA@youngkwangchaeScore6060
Encouraging results from #AACR26 on Elisrasib (D3S-001) for KRAS G12C NSCLC by Dr. Cho
Same topic elisrasib · 11 people KRASHeat 1410 likes1 reply3 reposts
06:52
Raffaele Di Giacomo, PhD@sciqstScore6060
Mesmerizing developments at #AACR26 indeed! It's interesting to see how Elisrasib is performing across different line therapies. ORR vari...
Same topic elisrasib · 11 people KRASHeat 00 likes0 replies0 reposts
04:24
Oriol Mirallas MD@DrMirallasScore6060
#AACR26
Same topic elisrasib · 11 people STK11 #NSCLC #KRASG12CHeat 5843 likes2 replies13 reposts
02:12
AACR@AACRScore6060
Responses to elisrasib were seen both in patients who were naïve for KRAS G12C inhibitor therapy and in those whose disease progressed on...
Same topic elisrasib · 11 people KRASHeat 32 likes0 replies1 repost